Premium Phosphosite-Specific 7TM Antibodies
Your Resource for GPCR Research
Select Your Country of Delivery below

G Protein-coupled Estrogen Receptor Antibodies

Close filters
No results were found for the filter!
Rabbit Monoclonal
NEW
GPER/GPR30 [UMB27] (RM-non-phospho-G Protein-Coupled Estrogen Receptor Antibody), Rabbit Monoclonal
GPER/GPR30 [UMB27] (RM-non-phospho-G...
The non-phospho-GPER/GPR30 antibody is directed against the distal end of the carboxyl-terminal tail of human GPER/GPR30. It can be used to detect total GPER/GPR30 receptors in Western blots independent of phosphorylation. The GPER/GPR30...
CHF495.00 *
Rabbit Monoclonal
NEW
GPER/GPR30 [UMB27] (RM-IHC-Grade-G Protein-Coupled Estrogen Receptor Antibody), Rabbit Monoclonal
GPER/GPR30 [UMB27] (RM-IHC-Grade-G...
The non-phospho-GPER/GPR30 antibody is directed against the distal end of the carboxyl-terminal tail of human GPER/GPR30. It can be used to detect total GPER/GPR30 receptors in Western blots independent of phosphorylation. The GPER/GPR30...
CHF495.00 *

The CaS (Calcium-sensing receptor) is a class C G protein–coupled receptor that plays a central role in extracellular calcium homeostasis. Pharmacologically, CaS is activated primarily by extracellular Ca²⁺ ions, as well as other polyvalent cations and certain amino acids that act as allosteric modulators. Upon activation, CaS couples mainly to Gq/11 and Gi/o proteins, leading to phospholipase C activation, intracellular calcium mobilization, inhibition of adenylyl cyclase, and modulation of MAPK signaling pathways. CaS is highly expressed in the parathyroid glands and kidneys, where it regulates parathyroid hormone secretion and renal calcium reabsorption, and it is also found in bone and the gastrointestinal tract. Clinically, CaS is targeted by calcimimetics such as Cinacalcet and Etelcalcetide, which act as positive allosteric modulators and are used to treat secondary hyperparathyroidism. Negative allosteric modulators, known as calcilytics, have been investigated for osteoporosis and related disorders, although none are widely approved. Ongoing structural and pharmacological research aims to develop more selective CaS modulators with improved safety and efficacy profiles. For more information on CaS receptor pharmacology please refer to the IUPHAR database. For further reading refer to:

Davenport AP, Bonner TI, Foord SM, Harmar AJ, Neubig RR, Pin JP, Spedding M, Kojima M, Kangawa K. International Union of Pharmacology. LVI. Ghrelin receptor nomenclature, distribution, and function. Pharmacol Rev. 2005 Dec;57(4):541-6. doi: 10.1124/pr.57.4.1. PMID: 16382107.

Ge X, Yang H, Bednarek MA, Galon-Tilleman H, Chen P, Chen M, Lichtman JS, Wang Y, Dalmas O, Yin Y, Tian H, Jermutus L, Grimsby J, Rondinone CM, Konkar A, Kaplan DD. LEAP2 Is an Endogenous Antagonist of the Ghrelin Receptor. Cell Metab. 2018 Feb 6;27(2):461-469.e6. doi: 10.1016 j.cmet.2017.10.016. PMID: 29233536.

The CaS ( Calcium-sensing receptor ) is a class C G protein–coupled receptor that plays a central role in extracellular calcium homeostasis. Pharmacologically, CaS is activated primarily by... read more »
Close window
G Protein-coupled Estrogen Receptor Antibodies

The CaS (Calcium-sensing receptor) is a class C G protein–coupled receptor that plays a central role in extracellular calcium homeostasis. Pharmacologically, CaS is activated primarily by extracellular Ca²⁺ ions, as well as other polyvalent cations and certain amino acids that act as allosteric modulators. Upon activation, CaS couples mainly to Gq/11 and Gi/o proteins, leading to phospholipase C activation, intracellular calcium mobilization, inhibition of adenylyl cyclase, and modulation of MAPK signaling pathways. CaS is highly expressed in the parathyroid glands and kidneys, where it regulates parathyroid hormone secretion and renal calcium reabsorption, and it is also found in bone and the gastrointestinal tract. Clinically, CaS is targeted by calcimimetics such as Cinacalcet and Etelcalcetide, which act as positive allosteric modulators and are used to treat secondary hyperparathyroidism. Negative allosteric modulators, known as calcilytics, have been investigated for osteoporosis and related disorders, although none are widely approved. Ongoing structural and pharmacological research aims to develop more selective CaS modulators with improved safety and efficacy profiles. For more information on CaS receptor pharmacology please refer to the IUPHAR database. For further reading refer to:

Davenport AP, Bonner TI, Foord SM, Harmar AJ, Neubig RR, Pin JP, Spedding M, Kojima M, Kangawa K. International Union of Pharmacology. LVI. Ghrelin receptor nomenclature, distribution, and function. Pharmacol Rev. 2005 Dec;57(4):541-6. doi: 10.1124/pr.57.4.1. PMID: 16382107.

Ge X, Yang H, Bednarek MA, Galon-Tilleman H, Chen P, Chen M, Lichtman JS, Wang Y, Dalmas O, Yin Y, Tian H, Jermutus L, Grimsby J, Rondinone CM, Konkar A, Kaplan DD. LEAP2 Is an Endogenous Antagonist of the Ghrelin Receptor. Cell Metab. 2018 Feb 6;27(2):461-469.e6. doi: 10.1016 j.cmet.2017.10.016. PMID: 29233536.

Recently viewed